Purpose: To determine the effect of intravitreal bevacizumab (lYB) on neovascular glaucoma (NVG)in terms of intraocular pressure (IOP), iris neovascularization (NVI) and best-corrected visual acuity (BCVA). Methods: In this randomized controlled trial, 26 eyes of 26 patients with NVG receiving conventional treatment were randomly allocated to three 2.5 mg IYB injections at 4-week intervals or a sham procedure (subconjunctival normal saline) at similar time intervals and in the same setting. Changes in IOP, extent of NVI and BCVA were compared between the two groups.Results: Overall, 14 eyes of 14 patients received IVB and 12 eyes of 12 subjects were allocated to the sham procedure and followed for a mean period of 5.9±1.4 months. The study arms were balanced regarding age, sex, cause of NVG, BCVA, IOP, and extent of NVI. The IVB group demonstrated significant reduction in mean lOP from a baseline value of 33.4±14.5 mmHg to 21.8±13.7 mmHg (P=0.007), 25.1±20.0 mmHg (P=0.058) and 23.9±18.7 mmHg (P=0.047) one, three and six months after intervention respectively. Mean NVI was also significantly reduced from a mean baseline value of 347±48° to 206±185° (P=0.01), 180±187° (P=0.004) and 180±180° (P=0.004) one, three and six months after intervention respectively. Mean IOP in the sham group was 32.3±14.3 mmHg prior to intervention and 34.9±15.2 mmHg (P=0.046), 35.2±10.7mmHg (P=0.29) and 32.2±7.3 mmHg (P=0.92) at one, three and six months after the injection respectively. Mean NVI in the sham group increased insignificantly from a baseline value of 270±138° to 277±130° (P=0.34), 300±117° (P=0.22) and 324±114° (P=0.34) one, three and six months after intervention respectively. No significant change in BCVA was observed within the study groups at any time interval.Conclusion: Intravitreal injections of bevacizumab seem to significantly reduce the extent of NVI and lOP in neovascular glaucoma, but may not affect visual acuity.